N/A N=9 Supportive Care

Hair Loss Prevention Study for Pancreatic Cancer

Alopecia

Bottom Line

View on ClinicalTrials.gov: NCT04492800 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2026

Primary outcome: Primary: Hair Preservation — 2; 3 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Paxman Scalp Cooling Device (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: HonorHealth Research Institute
Primary completion: Apr 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY Hair Preservation	2; 3	—
SECONDARY Patient Comfort	5; 0; 0; 0; 0	—
SECONDARY Chemotherapy-Induced Alopecia Distress	23	—

Summary

Pilot study intended for hair loss prevention in patients with pancreatic cancer who are receiving treatment containing nab-paclitaxel, gemcitabine and cisplatin.

Eligibility Criteria

Inclusion Criteria

Willing and able to provide written informed consent/assent for the trial
>18 years of age on day of signing informed consent
Diagnosis of pancreatic cancer and scheduled to receive treatment with a regimen containing nab-paclitaxel, gemcitabine and cisplatin

Exclusion Criteria

Grade 1 alopecia
Existing history of scalp metastases or the presence of scalp metastases is suspected
No history of previous cancers within the past 5 years
Central Nervous System (CNS) malignancies (either primary or metastatic)
Cold sensitivity, cold agglutinin disease, cryoglobulinemia, cryofibrinogenemia, cold migraine, cold urticaria, post-traumatic cold dystrophy
Imminent bone marrow ablation chemotherapy
Imminent skull radiation
Previously received or scheduled to undergo skull irradiation
Severe liver or renal disease from any etiology as patient may not be able to metabolize or clear the metabolites of the chemotherapeutic agent
Skin cancers including melanoma, squamous cell carcinoma and Merkel cell carcinoma
Small cell carcinoma of the lung
Solid tumors that have a high likelihood for metastasis in transit
Squamous cell carcinoma of the lung

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04492800). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.